Exobiosphere Joins Top Incubator for Space-based Drug Development
LUXEMBOURG – Exobiosphere, a leading innovator in space-based high-throughput screening for drug discovery, is excited to announce its acceptance into the highly competitive House of BioHealth's BioIncubator in Luxembourg. With cutting-edge facilities and resources dedicated to advancing biotech, digital health, and space health innovation, this milestone enables Exobiosphere to accelerate its mission of revolutionizing drug discovery by leveraging microgravity for unprecedented breakthroughs in the pharmaceutical and biotech sectors.
Located in Esch-sur-Alzette, the House of BioHealth provides Exobiosphere access to specialized laboratory spaces equipped with advanced imaging systems, bioinformatics tools, and robotics essential for high-throughput screening in microgravity environments. This setting ensures that Exobiosphere has the optimal environment for developing, testing, and refining its platform, allowing for deeper insights and more efficient drug discovery processes that offer significant potential to shorten development timelines and reduce R&D costs.
"The resources and partnerships available through House of BioHealth are unparalleled for advancing our mission to accelerate drug discovery,” said Kyle Acierno - CEO of Exobiosphere. “Being part of Luxembourg’s dynamic biotech ecosystem is invaluable as we work toward reducing development timelines and enhancing drug efficacy through space-based screening.”
Jean-Paul Scheuren, Administrator at the House of BioHealth, commented, “We are thrilled to welcome Exobiosphere to the House of BioHealth and strongly support their mission. The work they’re doing to leverage space-based environments for drug discovery aligns with our commitment to fostering pioneering projects that push the boundaries of biotech and health innovation.”
Silvia Colucci, Program Manager of the House of BioHealth, added, “Exobiosphere’s entry into our incubator program represents a powerful step forward in the intersection of space and health. Their innovative approach to drug discovery in microgravity has enormous potential to drive advancements that will benefit the biotech and pharmaceutical industries. We look forward to supporting their journey and are excited to see the impact of their work.”
The company’s unique approach to high-throughput screening in microgravity promises to advance drug discovery in diverse fields, from oncology to regenerative medicine, creating significant benefits for pharmaceutical companies and global health initiatives.
About Exobiosphere
Exobiosphere, headquartered in Luxembourg, develops high-throughput screening platforms in space to accelerate drug discovery. By conducting experiments in microgravity, Exobiosphere aims to streamline early-stage testing and improve the accuracy of drug discovery processes, providing invaluable insights to pharmaceutical, biotech, and healthcare companies.
About House of BioHealth
The House of BioHealth is a premier accelerator in Luxembourg, dedicated to supporting biotech and health tech innovation. With access to lab facilities, top research institutions, and a vibrant collaborative environment, it is instrumental in advancing Luxembourg’s life sciences ecosystem. It is the first step to the ambitious HE:AL Campus Project – a 100,000sqm development dedicated to Innovation in Health. More information can be found at House of BioHealth.
About BioIncubator Lab
The BioIncubator Lab is a specific accelerator programme that supports innovative start-up companies that have a particular interest to the Luxembourgish life science eco-system and match the Luxembourg Economic development strategy.